Mostrar el registro sencillo del ítem
dc.contributor.author
Elgart, Jorge Federico
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Glancszpigel, Mariana
dc.contributor.author
Albaytero, Natalia
dc.contributor.author
Kanevsky, Diego
dc.contributor.author
Rodriguez, Maria Florencia
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Mendizabal, Manuel
dc.contributor.author
Sánchez González, Yuri
dc.date.available
2024-04-05T14:05:07Z
dc.date.issued
2022-10
dc.identifier.citation
Elgart, Jorge Federico; Glancszpigel, Mariana; Albaytero, Natalia; Kanevsky, Diego; Rodriguez, Maria Florencia; et al.; Early Treatment of Hepatitis C Virus Improves Health Outcomes and Yields Cost-Savings: A Modeling Study in Argentina; Canadian Center of Science and Education; Global Journal of Health Science; 14; 11; 10-2022; 26-36
dc.identifier.issn
1916-9736
dc.identifier.uri
http://hdl.handle.net/11336/232136
dc.description.abstract
OBJECTIVE: Most untreated hepatitis C virus (HCV) patients develop chronic infection and severe complications, including death. Direct-acting antivirals in early stages of liver fibrosis reduce complications and healthcare costs. However, therapy is often delayed, and patients in early stages have limited access to effective treatments. We assessed the clinical and economic effect of treating chronic HCV at early versus late stages of disease in Argentina. METHODS: A Markov model of the natural HCV history was used to forecast lifetime liver-related and economic outcomes from social security sector perspective. Healthcare use and transition probabilities were drawn from literature. Demographic characteristics of the patients and treatment attributes were based on data from registrational trials of glecaprevir/pibrentasvir. RESULTS: Lower rates of all hepatic complications and liver-related mortality were predicted when treatment was initiated in mild versus advanced disease. Sustained virologic response rates were similar among all stages. Higher quality-adjusted life years (QALYs) were predicted when treatment was initiated in mild (F0-F1) versus moderate (F2-F3) or advanced (F4) liver disease (11.5, 9.9, and 7.5 QALYs, respectively). Delaying treatment increased long-term total lifetime costs (F4: AR$ 1 437 816; F2-F3: AR$ 967 673; F0-F1: AR$ 954 018; 37.10 AR$=1 USD, Nov 2018 exchange rate) and provided fewer QALYs. CONCLUSIONS: Our study show early treatment was a dominant strategy compared with treatment in advanced stages of liver disease. These results may help health policy makers take actions to reduce health and economic burden of HCV in Argentina.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Canadian Center of Science and Education
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/
dc.subject
HEPATITIS C VIRUS
dc.subject
COST-EFFECTIVENESS
dc.subject
DIRECT-ACTING ANTIVIRAL
dc.subject
PAN-GENOTYPE
dc.subject.classification
Otras Ciencias Médicas
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Otras Ciencias Médicas
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Early Treatment of Hepatitis C Virus Improves Health Outcomes and Yields Cost-Savings: A Modeling Study in Argentina
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2023-07-07T18:40:18Z
dc.identifier.eissn
1916-9744
dc.journal.volume
14
dc.journal.number
11
dc.journal.pagination
26-36
dc.journal.pais
Canadá
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.description.fil
Fil: Elgart, Jorge Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Endocrinología Experimental y Aplicada. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Centro de Endocrinología Experimental y Aplicada; Argentina
dc.description.fil
Fil: Glancszpigel, Mariana. 3Eff; Argentina
dc.description.fil
Fil: Albaytero, Natalia. 3eff; Argentina
dc.description.fil
Fil: Kanevsky, Diego. Abbvie Argentina; Argentina
dc.description.fil
Fil: Rodriguez, Maria Florencia. Abbvie Argentina; Argentina
dc.description.fil
Fil: Mendizabal, Manuel. Universidad Austral. Hospital Universitario Austral; Argentina
dc.description.fil
Fil: Sánchez González, Yuri. AbbVie Inc.; Estados Unidos
dc.journal.title
Global Journal of Health Science
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://ccsenet.org/journal/index.php/gjhs/article/view/0/47965
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.5539/gjhs.v14n11p26
Archivos asociados